Central administration of Dapagliflozin alleviates a hypothalamic neuroinflammatory signature and changing tubular lipid metabolism in type 2 diabetic nephropathy by upregulating MCPIP1 - 11/11/23
Abstract |
Background |
Hypothalamic neuroinflammation is associated with disorders of lipid metabolism. Considering the anti-neuroinflammation effects of sodium-glucose cotransporter 2(SGLT2) inhibitors, a central administration of Dapagliflozin is postulated to provide hypothalamic protection and change lipid metabolism in kidney against diabetic kidney disease (DKD).
Methods |
Blood samples of DKD patients were collected. Male Sprague-Dawley (SD) rats with 30 mg/kg streptozotocin and a high-fat diet, db/db mice and palmitic acid (PA)-stimulated BV2 microglia were used for study models. 0.28 mg/3ul dapagliflozin was injected into the lateral ventricle in db/db mice. Genes and protein expression levels were determined by qPCR, western blotting, immunofluorescence, and immunohistochemistry staining. Secreted IL-1β and IL-6 were quantified by ELISA. Oil red O staining, lipidomic, and non-targeted metabolomics were performed to evaluate abnormal lipid metabolism in kidney.
Results |
The decrease of serum MCPIP1 was an independent risk factor for renal progression in DKD patients (OR=1.22, 95 %CI: 1.02–1.45, P = 0.033). Higher microglia marker IBA1 and lower MCPIP1 in the hypothalamus, as well as lipid droplet deposition increasing in the kidney were observed in DKD rats. Central dapagliflozin could reduce the blood sugar, hypothalamic inflammatory cytokines, lipid droplet deposition in renal tubular. Lipidomics and metabolomics results showed that dapagliflozin changed 37 lipids and 19 metabolites considered on promoting lipolysis. These lipid metabolism changes were attributed to dapagliflozin by upregulating MCPIP1, and inhibiting cytokines in the microglia induced by PA.
Conclusions |
Central administrated Dapagliflozin elicits an anti-inflammatory effect by upregulating MCPIP1 levels in microglia and changes lipid metabolism in kidney of DKD.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Serum MCPIP1 deficiency was an independent risk factor of DKD progression. |
• | Dapagliflozin upregulates MCPIP1 to inhibit PA induced microglia activation. |
• | Centrally administrated SGLT2i alleviates neuroinflammation and renal lipid metabolism in type 2 diabetic nephropathy. |
Keywords : Diabetic nephropathy, Hypothalamic inflammation, Renal lipid metabolism, Monocyte chemoattractant protein-induced protein 1, Sodium-glucose cotransporter 2
Plan
Vol 168
Article 115840- décembre 2023 Retour au numéro
Article précédent
- Chitosan nanomedicine containing RGD peptide and PAD4 inhibitor based on phenyl boronate coupling inhibition of primary tumor growth and lung metastasis
- Yijiang Jia, Ayijiang Taledaohan, Renbo Jia, Xin Wang, Yunshu Jia, Jiawang Liu, Yuji Wang
- Salvianolic acid A alleviates heart failure with preserved ejection fraction via regulating TLR/Myd88/TRAF/NF-κB and p38MAPK/CREB signaling pathways
- Awaguli Dawuti, Shuchan Sun, Ranran Wang, Difei Gong, Ruiqi Liu, Dewen Kong, Tianyi Yuan, Jian Zhou, Yang Lu, Shoubao Wang, Guanhua Du, Lianhua Fang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?